Analysts Set DaVita Inc. (NYSE:DVA) Price Target at $162.80

DaVita Inc. (NYSE:DVA) has received an average recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $162.80.

DVA has been the subject of a number of recent analyst reports. Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th.

DaVita Price Performance

Shares of DVA opened at $141.96 on Tuesday. DaVita has a twelve month low of $124.42 and a twelve month high of $179.60. The company has a market capitalization of $11.36 billion, a P/E ratio of 13.22, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94. The firm has a 50 day moving average of $160.86 and a 200 day moving average of $158.19. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities research analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of large investors have recently made changes to their positions in the company. Epoch Investment Partners Inc. purchased a new position in shares of DaVita in the fourth quarter worth approximately $55,100,000. Invesco Ltd. raised its position in DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after acquiring an additional 275,284 shares during the period. Iron Triangle Partners LP purchased a new position in shares of DaVita during the 4th quarter worth $38,946,000. Amundi grew its position in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after acquiring an additional 240,126 shares during the period. Finally, Bridgewater Associates LP increased its stake in shares of DaVita by 298.4% in the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock worth $35,888,000 after purchasing an additional 179,744 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.